cancers-logo

Journal Browser

Journal Browser

Risk of Skin Cancer: Non-Melanoma/Melanoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 882

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology, Venereology and Allergology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstraße 56, 44791 Bochum, Germany
Interests: epidemiology; pathogenesis; risk factors; prevention; diagnosis and treatment of skin cancers (melanoma, and non-melanoma skin cancers); chronic inflammatory skin diseases (psoriasis and hidradenitis suppurativa)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Risk factors of skin cancer include a number of individual and environmental factors.  Aside from UV exposure, which may be considered the most important risk factor, viral infection (HPV), smoking, exposure to coal, arsenic compounds, and X-rays represent important environmental factors. Immunosuppression also increases the risk of skin cancer significantly (not only in organ-transplant recipients but also in patients receiving immunosuppressive drugs due to immunopathological conditions). In addition, several patient-related individual factors, like age, pigmentation, genetic predisposition, multiple nevi, or scars from disease and burns, may predispose patients to skin cancer development. Taking into account demographic development, climate change, changed leisure activities, and increased application of immunomodulatory therapies, the exposure to skin cancer risk factors will increase in the future, and accordingly, skin cancer incidence is also likely to increase. Thus, knowledge of risk factors and measures to avoid exposure to them play a key role in strategies to prevent skin cancer. In this context, raising awareness about the risk of skin cancer represents a major challenge, requiring a multidisciplinary approach, including various health professionals.

I am pleased to invite you to submit original research studies or reviews to this Special Issue addressing risk factors of skin cancers, but also studies targeting these risk factors in order to prevent skin cancer development. Research areas may include all types of melanoma and non-melanoma skin cancer, including studies on epidemiology, precancerous lesions, oncogenic mechanisms, or diagnostic approaches that may serve as starting points for strategies for prevention of skin cancer. 

Looking forward to receiving your contributions.

Prof. Dr. Eggert Stockfleth
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • non-melanoma skin cancer
  • keratinocyte cancer
  • Merkel cell carcinoma
  • UV exposure
  • immunosuppression
  • skin cancer prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 816 KB  
Article
Survival Outcomes in the Canadian Merkel Cell Carcinoma Population Between 2000 and 2018 and Descriptive Comparison with the American Joint Committee on Cancer 8th Edition Staging System—A Study from the Pan-Canadian Merkel Cell Collaborative
by Brittany Dingley, Megan Delisle, Anne Light, Sameer Apte, Ranjeeta Mallick, Trevor Hamilton, Heather Stuart, Martha Talbot, Gregory McKinnon, Evan Jost, Eva Thiboutot, Valerie Francescutti, Salsabila Samman, Alexandra M. Easson, Angela Schellenberg, Shaila Merchant, Julie La, Kaitlin Vanderbeck, Frances C. Wright, David Berger-Richardson, Pamela Hebbard, Olivia Hershorn, Rami Younan, Erica Patocskai, Samuel Rodriguez-Qizilbash, Ari Meguerditchian, Vanina Tchuente, Suzanne Kazandjian, Alex Mathieson, Farisa Hossain, Jessika Hetu, Stephanie Johnson-Obaseki and Carolyn Nessimadd Show full author list remove Hide full author list
Cancers 2025, 17(19), 3238; https://doi.org/10.3390/cancers17193238 - 6 Oct 2025
Viewed by 623
Abstract
Background/Objectives: Merkel cell carcinoma (MCC) is an uncommon but aggressive skin malignancy with a rising incidence. Limited data exist on the survival of MCC patients in Canada. This study analyzes the survival of patients diagnosed with MCC in Canada between 2000 and [...] Read more.
Background/Objectives: Merkel cell carcinoma (MCC) is an uncommon but aggressive skin malignancy with a rising incidence. Limited data exist on the survival of MCC patients in Canada. This study analyzes the survival of patients diagnosed with MCC in Canada between 2000 and 2018 compared to those reported by the American Joint Committee on Cancer (AJCC) 8th edition. Risk factors included in the database were sex, age, and immunosuppression. Methods: We conducted a multicenter retrospective cohort study including patients diagnosed with stage I–IV MCC aged ≥18 from 10 Canadian university centers and three provinces. We evaluated differences in survival compared to the cohort included in the AJCC 8th edition. Results: Among 899 patients diagnosed with MCC in Canada, 327 (36.4%) had stage I, 195 (21.7%) had stage II, 305 (33.9%) had stage III, and 72 (8.0%) had stage IV at presentation. When examining risk factors, 61.1% (549) were male, 10.2% (92) were immunosuppressed, and age at diagnosis was 75 years (±11). The five-year overall survival for patients diagnosed in Canada at stage I was 56.8%, stage IIA 54.0%, stage IIB 28.0%, stage IIIA 52.7%, stage IIIB 40.2%, and stage IV 13.9%. Conclusions: Survival from MCC is low in Canada across all stages. Compared to the AJCC 8th edition, patients diagnosed with MCC in Canada have similar survival rates, except for patients diagnosed with stage IIIB, who have lower survival rates in the AJCC 8th edition. Further research is needed to improve the survival of this rare malignancy. Full article
(This article belongs to the Special Issue Risk of Skin Cancer: Non-Melanoma/Melanoma)
Show Figures

Figure 1

Back to TopTop